🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchTRIUMPH program (retatrutide) — Phase 3 trial design and endpoints Page 3

TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints

TrialTracker_MD Mon, Jun 8, 2026 at 4:40 AM 13 replies 202 viewsPage 3 of 3
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Jun 8, 2026 at 10:08 AM#11
TrialNerd_Beth said:
The glucagon component looks paradoxical and is not.

Bookmarking. The distinction being drawn above is the one nobody else makes. Adding it to my notes with a link back to this thread.

44 17MeganSA_TX, LarryQC_SD, wanda_boise and 41 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Jun 8, 2026 at 1:13 PM#12

Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

45 18matt_MKE, Dr.ReproEndo, lucas_SP_BR and 42 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Jun 8, 2026 at 4:17 PM#13
VanRx_Mike said:
Read four things before the headline number.

Pushing back on VanRx_Mike here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

Correct me if the detail matters more than I have assumed.

46 19hans_munich, jason_sac26, chris_chi24 and 43 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Jun 8, 2026 at 7:22 PM#14

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

47 20amsterdam_pete, LondonLisa, mike_nyc and 44 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 10:27 PM#15

Moderator note: a couple of off-topic posts removed. No action needed from anybody.

Last edited: Jun 9, 2026 at 2:27 AM
48 21PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 45 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
Survodutide (GCG/GLP-1) — MASH and obesity trial results16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register